Adam Feuerstein ✡️· @adamfeuerstein · X·· 20 小时前评分70
正文 · 机器翻译
Incyte $INCY 胰腺癌药物——靶向 KRAS G12D——公司在 #ESMO26 上表示，该药物可诱导持久的肿瘤应答 https://www.statnews.com/2026/10/26/incyte-esmo-pancreatic-cancer-incb161734-results/
1202 浏览 · 2 赞 · 0 转发 · 0 回复
会议摘要
Calderasib monotherapy in various KRAS G12C–mutated advanced solid tumors: Results from the phase 1 KANDLELIT-001 study
https://esmocongress.esmo.orgKrascendo 3: A randomised, phase III trial in progress of divarasib vs immunotherapy or observation in patients with resected, stage II-IIIB, KRAS G12C+ non-small cell lung cancer
https://esmocongress.esmo.org2683P按 NSCLC, metastatic 对上
First-line (1L) olomorasib + pembrolizumab in KRAS G12C-mutant NSCLC: Updated results from LOXO-RAS-20001 and SUNRAY-01
https://esmocongress.esmo.org来源：Adam Feuerstein ✡️ · x.com